Slingshot members are tracking this event:

Pfizer's (PFE) Supplemental New Drug Application for Ibrance/Letrozole in Postmenopausal Women with Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-negative (ER+, HER2-) Metastatic Breast Cancer Accepted for FDA Review

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 21, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Supplemental New Drug Application, Ibrance, Letrozole, Postmenopausal Women With Hr+ Mbc, Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2, Er+, Her2-, Her2- Metastatic Breast Cancer, Fda